Despite the fact that both PD1-Fc-OX40L and PD-1(L1) blocking and OX40 agonist antibodies target the same biological pathways, there are potential differences in the mechanism of action when engagement of those pathways is targeted to the tumor microenvironment. This evidence concerns the gene TNFRSF4 and neoplasm.